Min Sup Song

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi The functions and regulation of the PTEN tumour suppressor
    Min Sup Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, Massachuchetts 02215, USA
    Nat Rev Mol Cell Biol 13:283-96. 2012
  2. pmc Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner
    Min Sup Song
    Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 144:187-99. 2011
  3. pmc Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function
    Antonella Papa
    Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 157:595-610. 2014
  4. pmc Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition
    Enrique Gonzalez-Billalabeitia
    Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School Department of Medicine Divisions of On leave of absence Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia, Spain
    Cancer Discov 4:896-904. 2014
  5. pmc MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling
    Su Jung Song
    Cancer Genetics Program, Division of Genetics, Department of Medicine and Pathology, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Cell 154:311-24. 2013
  6. pmc Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation
    Laura Poliseno
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA 02215, USA
    Sci Signal 3:ra29. 2010
  7. pmc The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
    Min Sup Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 455:813-7. 2008
  8. pmc A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells
    Jlenia Guarnerio
    Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    Cancer Discov 5:396-409. 2015
  9. pmc Systemic elevation of PTEN induces a tumor-suppressive metabolic state
    Isabel Garcia-Cao
    Cancer Genetics Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 149:49-62. 2012

Collaborators

Detail Information

Publications9

  1. doi The functions and regulation of the PTEN tumour suppressor
    Min Sup Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, Massachuchetts 02215, USA
    Nat Rev Mol Cell Biol 13:283-96. 2012
    ..Our increasing knowledge of PTEN and pathologies in which its function is altered will undoubtedly inform the rational design of novel therapies...
  2. pmc Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner
    Min Sup Song
    Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 144:187-99. 2011
    ..This finding identifies a strategy for cancer patient stratification and, thus, optimization of targeted therapies. PAPERCLIP:..
  3. pmc Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function
    Antonella Papa
    Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 157:595-610. 2014
    ..Our findings reveal that PTEN loss and PTEN mutations are not synonymous and define a working model for the function and regulation of PTEN...
  4. pmc Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition
    Enrique Gonzalez-Billalabeitia
    Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School Department of Medicine Divisions of On leave of absence Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia, Spain
    Cancer Discov 4:896-904. 2014
    ..Our findings, therefore, identify a combinatorial treatment with PARP and PI3K inhibitors as an effective option for PTEN-deficient prostate cancer...
  5. pmc MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling
    Su Jung Song
    Cancer Genetics Program, Division of Genetics, Department of Medicine and Pathology, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Cell 154:311-24. 2013
    ..Taken together, our findings implicate miR-22 as a crucial epigenetic modifier and promoter of EMT and breast cancer stemness toward metastasis. ..
  6. pmc Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation
    Laura Poliseno
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA 02215, USA
    Sci Signal 3:ra29. 2010
    ..Thus, we have uncovered a proto-oncogenic miRNA-dependent network for PTEN regulation and defined the MCM7 locus as a critical factor in initiating prostate tumorigenesis...
  7. pmc The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
    Min Sup Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 455:813-7. 2008
    ....
  8. pmc A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells
    Jlenia Guarnerio
    Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    Cancer Discov 5:396-409. 2015
    ..Importantly, by taking advantage of this new platform, we demonstrate the key role of an aberrant LRF-DLK1-SOX9 pathway in the pathogenesis of undifferentiated sarcoma, with important therapeutic implications...
  9. pmc Systemic elevation of PTEN induces a tumor-suppressive metabolic state
    Isabel Garcia-Cao
    Cancer Genetics Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 149:49-62. 2012
    ....